Literature DB >> 6734710

Pharmacodynamics and pharmacokinetics of xipamide in patients with normal and impaired kidney function.

H Knauf, E Mutschler.   

Abstract

The effect of a single oral dose of 40 mg xipamide on urinary excretion of Na+, K+, Cl-, Ca2+ and Mg2+ in healthy subjects and in patients with varying degrees of renal impairment was compared with various conventional diuretics. Xipamide caused marked excretion of Na+ and Cl-, whereas the diuretic produced only moderate kaliuresis; urinary excretion of Ca2+ was increased in proportion to Na+, like the loop diuretics. Xipamide affected electrolyte excretion even in patients with a creatinine clearance below 30 ml/min, as do the loop diuretics, too. Therefore, the pharmacodynamic characteristics of xipamide are more like those of a loop diuretic than of a thiazide. Xipamide was good bioavailable, its t 1/2 beta was 7 h and urinary recovery of the undegraded drug was 40% of the given dose. In renal insufficiency, t 1/2 beta increased from 7 to only 9h, yielding a moderate increase in the AUC. Urinary recovery of the drug was reduced in proportion to the reduction in the creatinine clearance of the patient. Therefore, significant extrarenal elimination of the diuretic must be postulated, which suffices to prevent significant drug accumulation in renal failure.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734710     DOI: 10.1007/BF00542150

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  26 in total

Review 1.  The interrelationship between sodium and calcium fluxes across cell membranes.

Authors:  M P Blaustein
Journal:  Rev Physiol Biochem Pharmacol       Date:  1974       Impact factor: 5.545

2.  Effects of chlorothiazide and amipramizide (MK 870) on the renal excretion of calcium, phosphate and magnesium.

Authors:  C G Duarte
Journal:  Metabolism       Date:  1968-05       Impact factor: 8.694

3.  [Fluorimetric determination of xipamide in biological materials using a new fluorescence reagent].

Authors:  M Sobel; E Mutschler
Journal:  J Chromatogr       Date:  1980-07-11

4.  [The saluretic effect of xipamide (4-chloro-5-sulfamoyl-2',6'-salicyloxylilide) in normal subjects].

Authors:  F W Hempelmann; F Leuschner; W Liebenow
Journal:  Arzneimittelforschung       Date:  1975-02

5.  [Structure-activity relationships in the diuretic xipamide (4-chloro-5-sulfamoyl-2', 6' -salicyloxylidide)].

Authors:  W Liebenow; F Leuschner
Journal:  Arzneimittelforschung       Date:  1975-02

6.  The role of volume contraction in the hypocalciuric action of chlorothiazide.

Authors:  N Breslau; A M Moses; I M Weiner
Journal:  Kidney Int       Date:  1976-08       Impact factor: 10.612

7.  Xipamide in the management of renal, hepatic and cardiac oedema.

Authors:  C H Gold; M Viljoen
Journal:  S Afr Med J       Date:  1978-09-30

Review 8.  Calcium transport in the nephron.

Authors:  W N Suki
Journal:  Am J Physiol       Date:  1979-07

9.  Site of renal action of xipamide.

Authors:  C H Gold; M Viljoen
Journal:  Clin Pharmacol Ther       Date:  1979-05       Impact factor: 6.875

10.  Calcium and phosphate transport in isolated segments of rabbit Henle's loop.

Authors:  A S Rocha; J B Magaldi; J P Kokko
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

View more
  13 in total

1.  Constant K+/Na+ excretion ratio during peak diuresis after piretanide but insignificant K+ loss during 24 hours.

Authors:  H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  Saluretic effect of the loop diuretic torasemide in chronic renal failure. Interdependence of electrolyte excretion.

Authors:  H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Pharmacodynamic and kinetic considerations on diuretics as a basis for differential therapy.

Authors:  H Knauf; E Mutschler
Journal:  Klin Wochenschr       Date:  1991-04-04

4.  Prediction of diuretic mobilization of cirrhotic ascites by pretreatment fractional sodium excretion.

Authors:  H Knauf; E Wenk; J Schölmerich; K J Goerg; W Gerok; H G Leser; E Mutschler
Journal:  Klin Wochenschr       Date:  1990-06-05

Review 5.  Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations.

Authors:  P Reetze-Bonorden; J Böhler; E Keller
Journal:  Clin Pharmacokinet       Date:  1993-05       Impact factor: 6.447

Review 6.  Clinical pharmacokinetics of some newer diuretics.

Authors:  B Beermann; M Grind
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics and pharmacodynamics of torasemide.

Authors:  H Knauf; E Mutschler
Journal:  Clin Pharmacokinet       Date:  1998-01       Impact factor: 6.447

Review 8.  The loop diuretic torasemide in chronic renal failure. Pharmacokinetics and pharmacodynamics.

Authors:  H Knauf; H Spahn; E Mutschler
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 9.  Low-dose segmental blockade of the nephron rather than high-dose diuretic monotherapy.

Authors:  H Knauf; E Mutschler
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 10.  Xipamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy.

Authors:  B N Prichard; R N Brogden
Journal:  Drugs       Date:  1985-10       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.